ReviewThe Korean journal of helicobacter and upper gastrointestinal research2025
Eosinophilic Esophagitis: Emerging Insights Into Diagnosis and Management.
Review in The Korean journal of helicobacter and upper gastrointestinal research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Eosinophilic Esophagitis: No Longer a Rarity in Asia-A Growing Concern for Clinicians.The Korean journal of helicobacter and upper gastrointestinal research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Eosinophilic esophagitis (EoE) is a chronic, immune-mediated, esophageal disease characterized by eosinophilic infiltration and symptoms such as dysphagia, food impaction, and esophageal dysfunction. Advances in diagnostic tools, including the EoE Endoscopic Reference Score and the Eosinophilic Esophagitis Histologic Scoring System, have improved disease characterization and monitoring. First-line treatments, such as proton pump inhibitors and topical corticosteroids, achieve significant histological and clinical remission rates. Dietary approaches, including the six-food elimination diet and step-up strategies, provide effective non-pharmacological options, although adherence remains a challenge. Esophageal dilation is a safe and effective therapy for relieving symptoms of dysphagia caused by strictures. Emerging biological therapies, such as dupilumab, show promise for targeting specific inflammatory pathways and addressing refractory cases. Although current therapies have demonstrated efficacy, gaps remain in the optimization of long-term disease control and treatment sequencing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.